Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Aditum Bio is a biotech venture capital firm founded in 2019 by Joe Jimenez, the former CEO of Novartis, and Dr. Mark Fishman, the former President of the Novartis Institutes for BioMedical Research. The firm is headquartered in Oakland, California, and has quickly established itself as a key player in the biotech investment landscape. Aditum Bio focuses on improving patient outcomes by efficiently identifying and developing potentially first- and best-in-class therapies.
The firm operates with a unique company-creation model that allows for rapid formation and execution, advancing novel drug candidates into clinical trials. Aditum Bio has launched a total of 13 companies to date and is currently deploying capital from its third fund, which closed in early 2025 with a size of $428 million. This growth in fund size reflects increasing confidence from limited partners in Aditum Bio's investment strategy and operational capabilities.
Aditum Bio invests primarily in the translational stage of drug development, targeting critical areas such as obesity, depression, substance abuse, renal disease, and infectious diseases. The firm seeks to acquire preclinical assets from academic institutions, pharmaceutical companies, and international partners, spinning them into standalone biotech companies. This approach allows Aditum Bio to carry companies through the translational, Phase 1, and Phase 2 stages of development.
The firm’s investment strategy emphasizes a structured operational approach that enables the swift progression of drug candidates from concept to clinical trials. Aditum Bio's focus on innovative therapies in the biotech and healthcare sectors positions it as a significant player in the market, particularly in areas like autoimmune diseases, CNS disorders, and metabolic conditions. The firm typically invests across various stages, including pre-seed, seed, Series A, Series B, and growth equity, with check sizes varying based on the stage and potential of the investment.
Aditum Bio has successfully launched thirteen companies, showcasing its commitment to advancing innovative therapies. Notable portfolio companies include:
These companies reflect Aditum Bio's strategic focus on critical therapeutic areas and its ability to create value through its unique investment model.
Joe Jimenez - Co-Founder and Managing Director; previously served as CEO of Novartis, bringing extensive experience in the pharmaceutical industry.
Dr. Mark Fishman - Co-Founder and Chair of the Scientific Advisory Board; former President of the Novartis Institutes for BioMedical Research, with a strong background in biomedical research.
Praveena Kandula - Principal; has experience in venture capital and biotech investments, focusing on identifying promising therapeutic candidates.
Chris Klee - Operating Partner; provides operational support and strategic guidance to portfolio companies, leveraging his industry expertise.
Shyanne Ali - SVP Quality; oversees quality assurance and regulatory compliance for portfolio companies, ensuring adherence to industry standards.
To pitch Aditum Bio, founders should use the general contact page on their website. A well-structured pitch deck is essential and should include information about the scientific basis of the project, market potential, and the team's qualifications. Aditum Bio does not specify a formal application process, but a warm introduction can be beneficial.
Response times may vary, but founders should expect a thorough review process given the firm's focus on the translational stage of drug development.
In 2024, Aditum Bio launched Fund III, which closed with a size of $428 million, reflecting strong interest from limited partners. This fund aims to continue the firm's focus on innovative biotech investments.
Recently, Aditum Bio achieved a significant milestone with the sale of Versanis Bio to Eli Lilly for $1.9 billion, marking a notable exit in the firm's portfolio. Additionally, Tempero Bio secured $70 million in Series B financing to advance its drug candidate into Phase 2 trials for substance use disorders.
What are Aditum Bio's investment criteria?
Aditum Bio focuses on the translational stage of drug development, targeting areas such as obesity, depression, substance abuse, renal disease, and infectious diseases. The firm seeks to invest in preclinical assets that can be spun into standalone biotech companies.
How can I pitch to Aditum Bio?
Founders can submit inquiries through the general contact page on Aditum Bio's website. A well-prepared pitch deck should include details about the scientific basis of the project, market potential, and the team’s expertise.
What makes Aditum Bio different from other VCs?
Aditum Bio employs a unique company-creation model that allows for rapid formation and execution of biotech companies. This model enables the firm to advance drug candidates efficiently through the development pipeline.
What is the geographic focus of Aditum Bio?
The firm primarily operates in the United States, although it also partners with international entities, particularly in Asia, to access innovative assets.
What is the typical check size for investments?
Aditum Bio invests across various stages, including pre-seed, seed, Series A, Series B, and growth equity, with check sizes varying based on the stage and potential of the investment.
What kind of support does Aditum Bio provide to portfolio companies?
Aditum Bio adds value by leveraging its extensive industry experience and networks, facilitating access to funding, strategic partnerships, and operational support for its portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.